A top ASX 200 share with 'resilient earnings' growth to buy now

This expert sees a long run of earnings growth ahead for this top ASX 200 share.

| More on:
patient with doctor, medical company, medical insurance

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for a top S&P/ASX 200 Index (ASX: XJO) share that's been resiliently growing earnings and profits and is tipped to continue doing so?

Then you may wish to run your slide rule over ASX 200 biotech stock CSL Ltd (ASX: CSL).

The CSL share price is up 0.6% in afternoon trade today, currently at $310.26 a share. While that's down a touch since the stock hit a new record closing high of $312.15 on 23 July, it still sees CSL shares up 18.1% over the past 12 months. Or more than twice the 7.5% gains posted by the ASX 200.

Atop the potential for share price gains, CSL also pays two annual dividends. Over the past 12 months the company has paid out a total of $3.81 in dividends. At current prices, that sees CSL shares trading on a partly franked trailing dividend yield of 1.2%.

And according to Tim Sullivan, director at Integro Private Wealth, this ASX 200 share should be able to keep on outperforming "long into the future".

A core ASX 200 share to hold long-term

"CSL has been a consistent compounder for long-term shareholders," Sullivan said (quoted by The Australian Financial Review).

According to Sullivan:

With its resilient earnings stream and structural organic growth, combined with the optionality in its R&D pipeline the business should be able to continue to grow its earnings long into the future.

At the right price it should form a core part of an investor's portfolio.

What's been driving the CSL share price higher?

It's been quite some time since the ASX 200 share released any price-sensitive announcements.

In fact, that was all the way back on 13 February, when management released CSL's half-year results.

Investor interest was clearly piqued by the 11% year on year increase in six-month revenue (in constant currency), which came in at US$8.05 billion.

Net profit after tax (NPAT) leapt 20% from the prior corresponding half-year to US$1.94 billion.

Meanwhile, cash flow from operations was up 9% to $1.07 billion.

As for the balance sheet, the ASX 200 share ended the half year with net assets of $19.16 billion.

CSL is scheduled to release its full FY 2024 results tomorrow, 13 August.

The company's full-year guidance is for underlying profit after tax and amortisation to be between $2.9 billion and $3.0 billion (at constant currency). If CSL delivers within this range, that would see FY 2024 profits growing anywhere from 13% to 17% year over year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »